1
|
Mangarova DB, Reimann C, Kaufmann JO, Möckel J, Kader A, Adams LC, Ludwig A, Onthank D, Robinson S, Karst U, Helmer R, Botnar R, Hamm B, Makowski MR, Brangsch J. Elastin-specific MR probe for visualization and evaluation of an interleukin-1β targeted therapy for atherosclerosis. Sci Rep 2024; 14:20648. [PMID: 39232217 PMCID: PMC11375012 DOI: 10.1038/s41598-024-71716-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Accepted: 08/30/2024] [Indexed: 09/06/2024] Open
Abstract
Atherosclerosis is a chronic inflammatory condition of the arteries and represents the primary cause of various cardiovascular diseases. Despite ongoing progress, finding effective anti-inflammatory therapeutic strategies for atherosclerosis remains a challenge. Here, we assessed the potential of molecular magnetic resonance imaging (MRI) to visualize the effects of 01BSUR, an anti-interleukin-1β monoclonal antibody, for treating atherosclerosis in a murine model. Male apolipoprotein E-deficient mice were divided into a therapy group (01BSUR, 2 × 0.3 mg/kg subcutaneously, n = 10) and control group (no treatment, n = 10) and received a high-fat diet for eight weeks. The plaque burden was assessed using an elastin-targeted gadolinium-based contrast probe (0.2 mmol/kg intravenously) on a 3 T MRI scanner. T1-weighted imaging showed a significantly lower contrast-to-noise (CNR) ratio in the 01BSUR group (pre: 3.93042664; post: 8.4007067) compared to the control group (pre: 3.70679168; post: 13.2982156) following administration of the elastin-specific MRI probe (p < 0.05). Histological examinations demonstrated a significant reduction in plaque size (p < 0.05) and a significant decrease in plaque elastin content (p < 0.05) in the treatment group compared to control animals. This study demonstrated that 01BSUR hinders the progression of atherosclerosis in a mouse model. Using an elastin-targeted MRI probe, we could quantify these therapeutic effects in MRI.
Collapse
Affiliation(s)
- Dilyana Branimirova Mangarova
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
| | - Carolin Reimann
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
| | - Jan Ole Kaufmann
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
- Division 1.5 Protein Analysis, Federal Institute for Materials Research and Testing (BAM), Richard-Willstätter-Str. 11, 12489, Berlin, Germany
| | - Jana Möckel
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
| | - Avan Kader
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
- Department of Diagnostic and Interventional Radiology, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Lisa Christine Adams
- Department of Diagnostic and Interventional Radiology, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Antje Ludwig
- Department of Cardiology and Angiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany
- DZHK (German Center for Cardiovascular Research), Partner Site, Berlin, Germany
| | - David Onthank
- Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, MA, United States of America
| | - Simon Robinson
- Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, MA, United States of America
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, Westfälische Wilhelms-Universität Münster, Corrensstr. 48, 48149, Münster, Germany
| | - Rebecca Helmer
- Institute of Inorganic and Analytical Chemistry, Westfälische Wilhelms-Universität Münster, Corrensstr. 48, 48149, Münster, Germany
| | - Rene Botnar
- School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital Westminster Bridge Road, London, SE1 7EH, United Kingdom
- Wellcome Trust/EPSRC Centre for Medical Engineering, King's College London, London, United Kingdom
- BHF Centre of Excellence, King's College London, Denmark Hill Campus, 125 Coldharbour Lane, London, SE5 9NU, United Kingdom
- Escuela de Ingeniería, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Bernd Hamm
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
| | - Marcus Richard Makowski
- Department of Diagnostic and Interventional Radiology, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Julia Brangsch
- Department of Radiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany
| |
Collapse
|
2
|
Capuana F, Phinikaridou A, Stefania R, Padovan S, Lavin B, Lacerda S, Almouazen E, Chevalier Y, Heinrich-Balard L, Botnar RM, Aime S, Digilio G. Imaging of Dysfunctional Elastogenesis in Atherosclerosis Using an Improved Gadolinium-Based Tetrameric MRI Probe Targeted to Tropoelastin. J Med Chem 2021; 64:15250-15261. [PMID: 34661390 PMCID: PMC8558862 DOI: 10.1021/acs.jmedchem.1c01286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Dysfunctional elastin turnover plays a major role in the progression of atherosclerotic plaques. Failure of tropoelastin cross-linking into mature elastin leads to the accumulation of tropoelastin within the growing plaque, increasing its instability. Here we present Gd4-TESMA, an MRI contrast agent specifically designed for molecular imaging of tropoelastin within plaques. Gd4-TESMA is a tetrameric probe composed of a tropoelastin-binding peptide (the VVGS-peptide) conjugated with four Gd(III)-DOTA-monoamide chelates. It shows a relaxivity per molecule of 34.0 ± 0.8 mM-1 s-1 (20 MHz, 298 K, pH 7.2), a good binding affinity to tropoelastin (KD = 41 ± 12 μM), and a serum half-life longer than 2 h. Gd4-TESMA accumulates specifically in atherosclerotic plaques in the ApoE-/- murine model of plaque progression, with 2 h persistence of contrast enhancement. As compared to the monomeric counterpart (Gd-TESMA), the tetrameric Gd4-TESMA probe shows a clear advantage regarding both sensitivity and imaging time window, allowing for a better characterization of atherosclerotic plaques.
Collapse
Affiliation(s)
- Federico Capuana
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin 10126, Italy
| | - Alkystis Phinikaridou
- School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, United Kingdom
| | - Rachele Stefania
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, Turin 10126, Italy
| | - Sergio Padovan
- Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, Via Nizza 52, Torino 10126, Italy
| | - Begoña Lavin
- School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, United Kingdom.,Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Ciudad Universitaria s/n, Madrid 28040, Spain
| | - Sara Lacerda
- Centre de Biophysique Moléculaire, CNRS, UPR 4301, Université d'Orléans, Rue Charles Sadron, Orléans Cedex 2 45071, France
| | - Eyad Almouazen
- CNRS, LAGEPP UMR 5007, Univ Lyon, Université Claude Bernard Lyon 1, 43 boulevard du 11 novembre 1918, Villeurbanne 69622, France
| | - Yves Chevalier
- CNRS, LAGEPP UMR 5007, Univ Lyon, Université Claude Bernard Lyon 1, 43 boulevard du 11 novembre 1918, Villeurbanne 69622, France
| | - Laurence Heinrich-Balard
- INSA Lyon, CNRS, MATEIS, UMR5510, Univ Lyon, Université Claude Bernard Lyon 1, Villeurbanne 69100, France
| | - René M Botnar
- School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, London SE1 7EH, United Kingdom.,Escuela de Ingeniería, Pontificia Universidad Católica de Chile, Avda. Vicuña Mackenna, Santiago 4860, Chile
| | | | - Giuseppe Digilio
- Department of Science and Technologic Innovation, Università del Piemonte Orientale ″Amedeo Avogadro″, Viale T. Michel 11, Alessandria 15121, Italy
| |
Collapse
|
3
|
Zhou IY, Montesi SB, Akam EA, Caravan P. Molecular Imaging of Fibrosis. Mol Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00077-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
4
|
Abstract
Molecular magnetic resonance (MR) imaging utilizes molecular probes to provide added biochemical or cellular information to what can already be achieved with anatomical and functional MR imaging. This review provides an overview of molecular MR and focuses specifically on molecular MR contrast agents that provide contrast by shortening the T1 time. We describe the requirements for a successful molecular MR contrast agent and the challenges for clinical translation. The review highlights work from the last 5 years and places an emphasis on new contrast agents that have been validated in multiple preclinical models. Applications of molecular MR include imaging of inflammation, fibrosis, fibrogenesis, thromboembolic disease, and cancers. Molecular MR is positioned to move beyond detection of disease to the quantitative staging of disease and measurement of treatment response.
Collapse
Affiliation(s)
| | | | - Peter Caravan
- The Institute for Innovation in Imaging, A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
| |
Collapse
|
5
|
Lavin Plaza B, Phinikaridou A, Andia ME, Potter M, Lorrio S, Rashid I, Botnar RM. Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries. Arterioscler Thromb Vasc Biol 2020; 40:2159-2170. [PMID: 32673527 PMCID: PMC7447189 DOI: 10.1161/atvbaha.120.314387] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Evidence from preclinical and clinical studies has demonstrated that myocardial infarction promotes atherosclerosis progression. The impact of focal vascular inflammation on the progression and phenotype of remote atherosclerosis remains unknown. Approach and Results: We used a novel ApoE-/- knockout mouse model of sustained arterial inflammation, initiated by mechanical injury in the abdominal aorta. Using serial in vivo molecular MRI and ex vivo histology and flow cytometry, we demonstrate that focal arterial inflammation triggered by aortic injury, accelerates atherosclerosis in the remote brachiocephalic artery. The brachiocephalic artery atheroma had distinct histological features including increased plaque size, plaque permeability, necrotic core to collagen ratio, infiltration of more inflammatory monocyte subsets, and reduced collagen content. We also found that arterial inflammation following focal vascular injury evoked a prolonged systemic inflammatory response manifested as a persistent increase in serum IL-6 (interleukin 6). Finally, we demonstrate that 2 therapeutic interventions-pravastatin and minocycline-had distinct anti-inflammatory effects at the plaque and systemic level. CONCLUSIONS We show for the first time that focal arterial inflammation in response to vascular injury enhances systemic vascular inflammation, accelerates remote atheroma progression and induces plaques more inflamed, lipid-rich, and collagen-poor in the absence of ischemic myocardial injury. This inflammatory cascade is modulated by pravastatin and minocycline treatments, which have anti-inflammatory effects at both plaque and systemic levels that mitigate atheroma progression.
Collapse
Affiliation(s)
- Begoña Lavin Plaza
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.)
| | - Alkystis Phinikaridou
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.)
| | - Marcelo E Andia
- Radiology Department & Millennium Nucleus for Cardiovascular Magnetic Resonance (M.E.A.), Pontificia Universidad Católica de Chile
| | - Myles Potter
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.)
| | - Silvia Lorrio
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.)
| | - Imran Rashid
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.).,Case Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH (I.R.)
| | - Rene M Botnar
- From the School of Biomedical Engineering and Imaging Sciences, King's College London, United Kingdom (B.L.P., A.P., M.P., S.L., I.R., R.M.B.).,Escuela de Ingeniería (R.M.B.), Pontificia Universidad Católica de Chile
| |
Collapse
|
6
|
Gupta A, Caravan P, Price WS, Platas-Iglesias C, Gale EM. Applications for Transition-Metal Chemistry in Contrast-Enhanced Magnetic Resonance Imaging. Inorg Chem 2020; 59:6648-6678. [PMID: 32367714 DOI: 10.1021/acs.inorgchem.0c00510] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Contrast-enhanced magnetic resonance imaging (MRI) is an indispensable tool for diagnostic medicine. However, safety concerns related to gadolinium in commercial MRI contrast agents have emerged in recent years. For patients suffering from severe renal impairment, there is an important unmet medical need to perform contrast-enhanced MRI without gadolinium. There are also concerns over the long-term effects of retained gadolinium within the general patient population. Demand for gadolinium-free MRI contrast agents is driving a new wave of inorganic chemistry innovation as researchers explore paramagnetic transition-metal complexes as potential alternatives. Furthermore, advances in personalized care making use of molecular-level information have motivated inorganic chemists to develop MRI contrast agents that can detect pathologic changes at the molecular level. Recent studies have highlighted how reaction-based modulation of transition-metal paramagnetism offers a highly effective mechanism to achieve MRI contrast enhancement that is specific to biochemical processes. This Viewpoint highlights how recent advances in transition-metal chemistry are leading the way for a new generation of MRI contrast agents.
Collapse
Affiliation(s)
- Abhishek Gupta
- Nanoscale Organisation and Dynamics Group, School of Science and Health, Western Sydney University, Penrith, New South Wales 2751, Australia.,Ingham Institute of Applied Medical Research, Liverpool, New South Wales 2170, Australia
| | | | - William S Price
- Nanoscale Organisation and Dynamics Group, School of Science and Health, Western Sydney University, Penrith, New South Wales 2751, Australia.,Ingham Institute of Applied Medical Research, Liverpool, New South Wales 2170, Australia
| | - Carlos Platas-Iglesias
- Centro de Investigacións Científicas Avanzadas and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, A Coruña, Galicia 15071, Spain
| | | |
Collapse
|
7
|
Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. Int J Mol Sci 2020; 21:ijms21082992. [PMID: 32340284 PMCID: PMC7216001 DOI: 10.3390/ijms21082992] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 04/02/2020] [Accepted: 04/15/2020] [Indexed: 12/13/2022] Open
Abstract
Atherosclerosis is a lipoprotein-driven inflammatory disorder leading to a plaque formation at specific sites of the arterial tree. After decades of slow progression, atherosclerotic plaque rupture and formation of thrombi are the major factors responsible for the development of acute coronary syndromes (ACSs). In this regard, the detection of high-risk (vulnerable) plaques is an ultimate goal in the management of atherosclerosis and cardiovascular diseases (CVDs). Vulnerable plaques have specific morphological features that make their detection possible, hence allowing for identification of high-risk patients and the tailoring of therapy. Plaque ruptures predominantly occur amongst lesions characterized as thin-cap fibroatheromas (TCFA). Plaques without a rupture, such as plaque erosions, are also thrombi-forming lesions on the most frequent pathological intimal thickening or fibroatheromas. Many attempts to comprehensively identify vulnerable plaque constituents with different invasive and non-invasive imaging technologies have been made. In this review, advantages and limitations of invasive and non-invasive imaging modalities currently available for the identification of plaque components and morphologic features associated with plaque vulnerability, as well as their clinical diagnostic and prognostic value, were discussed.
Collapse
|
8
|
Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging. Sci Rep 2020; 10:79. [PMID: 31919465 PMCID: PMC6952459 DOI: 10.1038/s41598-019-57075-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 12/22/2019] [Indexed: 12/16/2022] Open
Abstract
Molecular imaging of atherosclerosis by Magnetic Resonance Imaging (MRI) has been impaired by a lack of validation of the specific substrate responsible for the molecular imaging signal. We therefore aimed to investigate the additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecular MRI of atherosclerotic plaques. Atherosclerotic Ldlr−/− mice were investigated by high-field MRI (7 T) at different time points following injection of atherosclerosis-affine Gadofluorine P as well as at different stages of atherosclerosis formation (4, 8, 16 and 20 weeks of HFD). At each imaging time point mice were immediately sacrificed after imaging and aortas were excised for mass spectrometry imaging: Matrix Assisted Laser Desorption Ionization (MALDI) Imaging and Laser Ablation – Inductively Coupled Plasma – Mass Spectrometry (LA-ICP-MS) imaging. Mass spectrometry imaging allowed to visualize the localization and measure the concentration of the MR imaging probe Gadofluorine P in plaque tissue ex vivo with high spatial resolution and thus adds novel and more target specific information to molecular MR imaging of atherosclerosis.
Collapse
|
9
|
Sui B, Gao P. High-resolution vessel wall magnetic resonance imaging of carotid and intracranial vessels. Acta Radiol 2019; 60:1329-1340. [PMID: 30727746 DOI: 10.1177/0284185119826538] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Binbin Sui
- Radiology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China
- Radiology Department, Beijing Neurosurgical Institute, Beijing, PR China
- Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, PR China
| | - Peiyi Gao
- Radiology Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China
- Radiology Department, Beijing Neurosurgical Institute, Beijing, PR China
- Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, PR China
| |
Collapse
|
10
|
Li Z, Zheng Z, Ding J, Li X, Zhao Y, Kang F, Li Y, Pang L, Du W, Wu Z, Zhu P. Contrast-enhanced Ultrasonography for Monitoring Arterial Inflammation in Takayasu Arteritis. J Rheumatol 2019; 46:616-622. [PMID: 30824642 DOI: 10.3899/jrheum.180701] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2018] [Indexed: 02/08/2023]
Abstract
OBJECTIVE To evaluate the utility of contrast-enhanced ultrasound (CEUS) compared with 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in assessing vessel inflammation of Takayasu arteritis (TA). METHODS This is a retrospective analysis of 71 patients with TA who had undergone carotid CEUS. Twenty-two of 71 patients underwent FDG-PET after CEUS. Clinical disease activity was assessed by Kerr criteria and the Indian Takayasu Clinical Activity Score 2010 (ITAS2010). We investigated the correlation between carotid vascularization on CEUS and clinical data. The consistency of carotid CEUS and PET data has been analyzed for TA disease activity. RESULTS There was a statistically significant correlation between the results of CEUS and ITAS2010 (p = 0.004) or Kerr criteria (p < 0.001). According to ITAS2010, thirty-four of 71 patients with TA were clinically inactive. Assessment of 34 TA patients with clinically inactive disease yielded 11 CEUS scans that showed active lesions (visual grade ≥ 2) in the left or right carotid artery. In 22 cases that underwent CEUS and FDG-PET, 12 were active and 10 were inactive on the basis of ITAS2010. Moreover, bilateral carotid CEUS vascularization score positively correlated with vascular FDG uptake in these patients with TA (p = 0.004). When vascular inflammation was defined as FDG uptake with visual grade ≥ 2, carotid CEUS showed sensitivity of 100% and specificity of 80%. CONCLUSION For TA patients with clinically inactive disease, CEUS could help clinicians to identify active lesions in the carotid vascular region. Carotid CEUS may be a rapid and cost-effective imaging tool in the followup of patients with TA.
Collapse
Affiliation(s)
- ZhiQin Li
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - ZhaoHui Zheng
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - Jin Ding
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - XiaoFeng Li
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - YongFeng Zhao
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - Fei Kang
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - Ying Li
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - LinXuan Pang
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - WangLei Du
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - ZhenBiao Wu
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China.,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work
| | - Ping Zhu
- From the Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, China. .,Z.Q. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.H. Zheng, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; J. Ding, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; X.F. Li, MS, Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University; Y.F. Zhao, MS, Department of Ultrasound, Xijing Hospital, Fourth Military Medical University; F. Kang, MD, PhD, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University; Y. Li, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; L.X. Pang, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; W.L. Du, MS, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; Z.B. Wu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University; P. Zhu, MD, PhD, Department of Clinical Immunology, Institute of Rheumatism and Immunity, PLA, Xijing Hospital, Fourth Military Medical University. ZhiQin Li and ZhaoHui Zheng contributed equally to this work.
| |
Collapse
|
11
|
Désogère P, Montesi SB, Caravan P. Molecular Probes for Imaging Fibrosis and Fibrogenesis. Chemistry 2019; 25:1128-1141. [PMID: 30014529 PMCID: PMC6542638 DOI: 10.1002/chem.201801578] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Indexed: 12/26/2022]
Abstract
Fibrosis, or the accumulation of extracellular matrix molecules that make up scar tissue, is a common result of chronic tissue injury. Advances in the clinical management of fibrotic diseases have been hampered by the low sensitivity and specificity of noninvasive early diagnostic options, lack of surrogate end points for use in clinical trials, and a paucity of noninvasive tools to assess fibrotic disease activity longitudinally. Hence, the development of new methods to image fibrosis and fibrogenesis is a large unmet clinical need. Herein, an overview of recent and selected molecular probes for imaging of fibrosis and fibrogenesis by magnetic resonance imaging, positron emission tomography, and single photon emission computed tomography is provided.
Collapse
Affiliation(s)
- Pauline Désogère
- The Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA
- The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, 02128, USA
| | - Sydney B Montesi
- Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, 02114, USA
| | - Peter Caravan
- The Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA
- The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, 02128, USA
| |
Collapse
|
12
|
Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev 2019; 119:957-1057. [PMID: 30350585 PMCID: PMC6516866 DOI: 10.1021/acs.chemrev.8b00363] [Citation(s) in RCA: 849] [Impact Index Per Article: 169.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Tens of millions of contrast-enhanced magnetic resonance imaging (MRI) exams are performed annually around the world. The contrast agents, which improve diagnostic accuracy, are almost exclusively small, hydrophilic gadolinium(III) based chelates. In recent years concerns have arisen surrounding the long-term safety of these compounds, and this has spurred research into alternatives. There has also been a push to develop new molecularly targeted contrast agents or agents that can sense pathological changes in the local environment. This comprehensive review describes the state of the art of clinically approved contrast agents, their mechanism of action, and factors influencing their safety. From there we describe different mechanisms of generating MR image contrast such as relaxation, chemical exchange saturation transfer, and direct detection and the types of molecules that are effective for these purposes. Next we describe efforts to make safer contrast agents either by increasing relaxivity, increasing resistance to metal ion release, or by moving to gadolinium(III)-free alternatives. Finally we survey approaches to make contrast agents more specific for pathology either by direct biochemical targeting or by the design of responsive or activatable contrast agents.
Collapse
Affiliation(s)
- Jessica Wahsner
- Athinoula A. Martinos Center for Biomedical Imaging and the Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Eric M. Gale
- Athinoula A. Martinos Center for Biomedical Imaging and the Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Aurora Rodríguez-Rodríguez
- Athinoula A. Martinos Center for Biomedical Imaging and the Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| | - Peter Caravan
- Athinoula A. Martinos Center for Biomedical Imaging and the Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
| |
Collapse
|
13
|
Ramos IT, Henningsson M, Nezafat M, Lavin B, Lorrio S, Gebhardt P, Protti A, Eykyn TR, Andia ME, Flögel U, Phinikaridou A, Shah AM, Botnar RM. Simultaneous Assessment of Cardiac Inflammation and Extracellular Matrix Remodeling after Myocardial Infarction. Circ Cardiovasc Imaging 2018; 11:e007453. [PMID: 30524648 PMCID: PMC6277008 DOI: 10.1161/circimaging.117.007453] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Accepted: 08/04/2018] [Indexed: 01/25/2023]
Abstract
Background Optimal healing of the myocardium following myocardial infarction (MI) requires a suitable degree of inflammation and its timely resolution, together with a well-orchestrated deposition and degradation of extracellular matrix (ECM) proteins. Methods and Results MI and SHAM-operated animals were imaged at 3,7,14 and 21 days with 3T magnetic resonance imaging (MRI) using a 19F/1H surface coil. Mice were injected with 19F-perfluorocarbon (PFC) nanoparticles to study inflammatory cell recruitment, and with a gadolinium-based elastin-binding contrast agent (Gd-ESMA) to evaluate elastin content. 19F MRI signal co-localized with infarction areas, as confirmed by late-gadolinium enhancement, and was highest 7days post-MI, correlating with macrophage content (MAC-3 immunohistochemistry) (ρ=0.89,P<0.0001). 19F quantification with in vivo (MRI) and ex vivo nuclear magnetic resonance (NMR) spectroscopy correlated linearly (ρ=0.58,P=0.020). T1 mapping after Gd-ESMA injection showed increased relaxation rate (R1) in the infarcted regions and was significantly higher at 21days compared with 7days post-MI (R1[s-1]:21days=2.8 [IQR,2.69-3.30] vs 7days=2.3 [IQR,2.12-2.5], P<0.05), which agreed with an increased tropoelastin content (ρ=0.89, P<0.0001). The predictive value of each contrast agent for beneficial remodeling was evaluated in a longitudinal proof-of-principle study. Neither R1 nor 19F at day 7 were significant predictors for beneficial remodeling (P=0.68;P=0.062). However, the combination of both measurements (R1<2.34Hz and 0.55≤19F≤1.85) resulted in an odds ratio of 30.0 (CI95%:1.41-638.15;P=0.029) for favorable post-MI remodeling. Conclusions Multinuclear 1H/19F MRI allows the simultaneous assessment of inflammation and elastin remodeling in a murine MI model. The interplay of these biological processes affects cardiac outcome and may have potential for improved diagnosis and personalized treatment.
Collapse
Affiliation(s)
- Isabel T Ramos
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, United Kingdom
| | - Markus Henningsson
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - Maryam Nezafat
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - Begoña Lavin
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, United Kingdom
| | - Silvia Lorrio
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, United Kingdom
| | - Pierre Gebhardt
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- Department of Physics of Molecular Imaging Systems, Institute for Experimental Molecular Imaging, RWTH Aachen University, Aachen, Germany
| | - Andrea Protti
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - Thomas R Eykyn
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
| | - Marcelo E Andia
- Radiology Department, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile
| | - Ulrich Flögel
- Department of Molecular Cardiology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
| | - Alkystis Phinikaridou
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, United Kingdom
| | - Ajay M Shah
- School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, London, United Kingdom
| | - René M Botnar
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom
- Escuela de Ingeniería, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|
14
|
Phinikaridou A, Lacerda S, Lavin B, Andia ME, Smith A, Saha P, Botnar RM. Tropoelastin: A novel marker for plaque progression and instability. Circ Cardiovasc Imaging 2018; 11. [PMID: 30214669 DOI: 10.1161/circimaging.117.007303] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background Elastolysis and ineffective elastogenesis favor the accumulation of tropoelastin, rather than cross-linked elastin, in atherosclerotic plaques. We developed gadolinium-labeled tropoelastin-specific magnetic resonance contrast agents (Gd-TESMAs) for tropoelastin imaging in animal models. Methods and Results Two peptides, VVGSPSAQDEASPLS and YPDHVQYTHY were selected to target tropoelastin. In vitro binding, relaxivity, and biodistribution experiments enabled characterization of the probes and selecting the best candidate for in vivo MRI. MRI was performed in atherosclerotic apolipoprotein E-deficient (ApoE-/-) mice and New Zealand white rabbits with stable and rupture-prone plaques using Gd-TESMA. Additionally, human carotid endarterectomy specimens were imaged ex vivo. The VVGSPSAQDEASPLS-based probe discriminated between tropoelastin and cross-linked elastin (64±7% vs 1±2%, P=0.001), had high in vitro relaxivity in solution (r1-free=11.7±0.6mM-1s-1, r1-bound to tropoelastin = 44±1mM-1s-1) and favorable pharmacokinetics. In vivo mice vascular enhancement (4wks=0.13±0.007mm2, 8wks=0.22±0.01mm2, 12wks=0.33±0.01mm2, P<0.001) and R1 relaxation rate (4wks=0.90±0.01 s-1, 8wks=1.40±0.03 s-1, 12wks=1.87±0.04s-1, P<0.001) increased with atherosclerosis progression after Gd-TESMA injection. Conversely, statin-treated (0.13±0.01mm2, R1 =1.37±0.03s-1) and control (0.10±0.005mm2, R1 =0.87±0.05s-1) mice showed less enhancement. Rupture-prone rabbit plaques had higher R1 relaxation rate compared with stale plaques (R1=2.26±0.1s-1vs R1=1.43±0.02s-1, P=0.001), after administration of Gd-TESMA that allowed detection of rupture-prone plaques with high sensitivity (84.4%) and specificity (92.3%). Increased vascular R1 relaxation rate was observed in carotid endarterectomy plaques after soaking (R1pre= 1.1±0.26 s-1 vs R1post= 3.0±0.1s-1, P=0.01). Ex vivo analyses confirmed the MRI findings and showed uptake of the contrast agent to be specific for tropoelastin. Conclusions MRI of tropoelastin provides a novel biomarker for atherosclerotic plaque progression and instability.
Collapse
Affiliation(s)
- Alkystis Phinikaridou
- School of Biomedical Engineering Imaging Sciences, King's College London, London, UK.,BHF Centre of Excellence, Cardiovascular Division, King's College London, London, UK
| | - Sara Lacerda
- School of Biomedical Engineering Imaging Sciences, King's College London, London, UK.,BHF Centre of Excellence, Cardiovascular Division, King's College London, London, UK
| | - Begoña Lavin
- School of Biomedical Engineering Imaging Sciences, King's College London, London, UK.,BHF Centre of Excellence, Cardiovascular Division, King's College London, London, UK
| | - Marcelo E Andia
- School of Biomedical Engineering Imaging Sciences, King's College London, London, UK.,Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Alberto Smith
- Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, London, UK
| | - Prakash Saha
- Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, London, UK
| | - René M Botnar
- School of Biomedical Engineering Imaging Sciences, King's College London, London, UK.,BHF Centre of Excellence, Cardiovascular Division, King's College London, London, UK.,Wellcome Trust and EPSRC Medical Engineering Center, King's College London, UK.,Pontificia Universidad Católica de Chile, Escuela de Ingeniería, Santiago, Chile
| |
Collapse
|
15
|
Anwaier G, Chen C, Cao Y, Qi R. A review of molecular imaging of atherosclerosis and the potential application of dendrimer in imaging of plaque. Int J Nanomedicine 2017; 12:7681-7693. [PMID: 29089763 PMCID: PMC5656339 DOI: 10.2147/ijn.s142385] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Despite the fact that technological advancements have been made in diagnosis and treatment, cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity worldwide. Early detection of atherosclerosis (AS), especially vulnerable plaques, plays a crucial role in the prevention of acute coronary syndrome (ACS). Targeting the critical cytokines and molecules that are upregulated during the biological process of AS by in vivo molecular imaging has been widely used in plaque imaging. With their three-dimensional architecture, composition, and abundant terminal functional groups, dendrimers provide a platform for multitargeting and multimodal imaging. Thus, modified dendrimers with the key molecules upregulated in AS plaques will be an innovative attempt to achieve targeted imaging of AS plaques specifically and efficiently. This review was aimed to address some recent works on imaging of AS plaques using various types of image technology and further discuss the applications of dendrimers, an innovative yet seldom used method in imaging of AS plaques due to some limitations and challenges, and we highlight the bright future of the modified dendrimers in characterizing AS plaques.
Collapse
Affiliation(s)
- Gulinigaer Anwaier
- Peking University Institute of Cardiovascular Sciences, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of education, Peking University Health Science Center.,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing.,School of Basic Medical Science, Shihezi University, Shihezi, Xinjiang, People's Republic of China
| | - Cong Chen
- Peking University Institute of Cardiovascular Sciences, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of education, Peking University Health Science Center.,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing
| | - Yini Cao
- Peking University Institute of Cardiovascular Sciences, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of education, Peking University Health Science Center.,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing
| | - Rong Qi
- Peking University Institute of Cardiovascular Sciences, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of education, Peking University Health Science Center.,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing.,School of Basic Medical Science, Shihezi University, Shihezi, Xinjiang, People's Republic of China
| |
Collapse
|
16
|
Reimann C, Brangsch J, Colletini F, Walter T, Hamm B, Botnar RM, Makowski MR. Molecular imaging of the extracellular matrix in the context of atherosclerosis. Adv Drug Deliv Rev 2017; 113:49-60. [PMID: 27639968 DOI: 10.1016/j.addr.2016.09.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 09/01/2016] [Accepted: 09/07/2016] [Indexed: 12/25/2022]
Abstract
This review summarizes the current status of molecular imaging of the extracellular matrix (ECM) in the context of atherosclerosis. Apart from cellular components, the ECM of the atherosclerotic plaque plays a relevant role during the initiation of atherosclerosis and its' subsequent progression. Important structural and signaling components of the ECM include elastin, collagen and fibrin. However, the ECM not only plays a structural role in the arterial wall but also interacts with different cell types and has important biological signaling functions. Molecular imaging of the ECM has emerged as a new diagnostic tool to characterize biological aspects of atherosclerotic plaques, which cannot be characterized by current clinically established imaging techniques, such as X-ray angiography. Different types of molecular probes can be detected in vivo by imaging modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET) and single photon emission computed tomography (SPECT). The modality specific signaling component of the molecular probe provides information about its spatial location and local concentration. The successful introduction of molecular imaging into clinical practice and guidelines could open new pathways for an earlier detection of disease processes and a better understanding of the disease state on a biological level. Quantitative in vivo molecular parameters could also contribute to the development and evaluation of novel cardiovascular therapeutic interventions and the assessment of response to treatment.
Collapse
Affiliation(s)
| | | | | | - Thula Walter
- Department of Radiology, Charité, Berlin, Germany
| | - Bernd Hamm
- Department of Radiology, Charité, Berlin, Germany
| | - Rene M Botnar
- King's College London, Division of Imaging Sciences, United Kingdom; Wellcome Trust and EPSRC Medical Engineering Center, United Kingdom; BHF Centre of Excellence, King's College London, London, United Kingdom; NIHR Biomedical Research Centre, King's College London, London, United Kingdom
| | - Marcus R Makowski
- Department of Radiology, Charité, Berlin, Germany; King's College London, Division of Imaging Sciences, United Kingdom.
| |
Collapse
|
17
|
Phinikaridou A, Andia ME, Lavin B, Smith A, Saha P, Botnar RM. Increased Vascular Permeability Measured With an Albumin-Binding Magnetic Resonance Contrast Agent Is a Surrogate Marker of Rupture-Prone Atherosclerotic Plaque. Circ Cardiovasc Imaging 2016; 9:e004910. [PMID: 27940955 PMCID: PMC5388187 DOI: 10.1161/circimaging.116.004910] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 09/30/2016] [Indexed: 12/21/2022]
Abstract
BACKGROUND Compromised structural integrity of the endothelium and higher microvessel density increase vascular permeability. We investigated whether vascular permeability measured in vivo by magnetic resonance imaging using the albumin-binding contrast agent, gadofosveset, is a surrogate marker of rupture-prone atherosclerotic plaque in a rabbit model. METHODS AND RESULTS New Zealand white rabbits (n=10) were rendered atherosclerotic by cholesterol-diet and endothelial denudation. Plaque rupture was triggered with Russell's viper venom and histamine. Animals were imaged pre-triggering, at 3 and 12 weeks, to quantify plaque area, vascular permeability, vasodilation, and stiffness and post-triggering to identify thrombus. Plaques identified on the pretrigger scans were classified as stable or rupture-prone based on the absence or presence of thrombus on the corresponding post-trigger magnetic resonance imaging, respectively. All rabbits had developed atherosclerosis, and 60% had ruptured plaques. Rupture-prone plaques had higher vessel wall relaxation rate (R1; 2.30±0.5 versus 1.86±0.3 s-1; P<0.001), measured 30 minutes after gadofosveset administration, and higher R1/plaque area ratio (0.70±0.06 versus 0.47±0.02, P= 0.01) compared with stable plaque at 12 weeks. Rupture-prone plaques had higher percent change in R1 between the 3 and 12 weeks compared with stable plaque (50.80±7.2% versus 14.22±2.2%; P<0.001). Immunohistochemistry revealed increased vessel wall albumin and microvessel density in diseased aortas and especially in ruptured plaque. Electron microscopy showed lack of structural integrity in both luminal and microvascular endothelium in diseased vessels. Functionally, the intrinsic vasodilation of the vessel wall decreased at 12 weeks compared with 3 weeks (18.60±1.0% versus 23.43±0.8%; P<0.001) and in rupture-prone compared with stable lesions (16.40±2.0% versus 21.63±1.2%; P<0.001). Arterial stiffness increased at 12 weeks compared with 3 weeks (5.00±0.1 versus 2.53±0.2 m/s; P<0.001) both in animals with stable and rupture-prone lesions. CONCLUSIONS T1 mapping using an albumin-binding contrast agent (gadofosveset) could quantify the changes in vascular permeability associated with atherosclerosis progression and rupture-prone plaques.
Collapse
Affiliation(s)
- Alkystis Phinikaridou
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.).
| | - Marcelo E Andia
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.)
| | - Begoña Lavin
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.)
| | - Alberto Smith
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.)
| | - Prakash Saha
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.)
| | - René M Botnar
- From the Division of Imaging Science and Biomedical Engineering (A.P., M.E.A., B.L., R.M.B.), Academic Department of Surgery, Cardiovascular Division (A.S., P.S.), BHF Centre of Excellence, Cardiovascular Division (A.S., R.M.B.), and Wellcome Trust and EPSRC Medical Engineering Center (P.S., R.M.B.), King's College London, United Kingdom; and Radiology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (M.E.A.)
| |
Collapse
|
18
|
Abstract
Molecular imaging offers great potential for noninvasive visualization and quantitation of the cellular and molecular components involved in atherosclerotic plaque stability. In this chapter, we review emerging molecular imaging modalities and approaches for quantitative, noninvasive detection of early biological processes in atherogenesis, including vascular endothelial permeability, endothelial adhesion molecule up-regulation, and macrophage accumulation, with special emphasis on mouse models. We also highlight a number of targeted imaging nanomaterials for assessment of advanced atherosclerotic plaques, including extracellular matrix degradation, proteolytic enzyme activity, and activated platelets using mouse models of atherosclerosis. The potential for clinical translation of molecular imaging nanomaterials for assessment of atherosclerotic plaque biology, together with multimodal approaches is also discussed.
Collapse
|
19
|
Preclinical models of atherosclerosis. The future of Hybrid PET/MR technology for the early detection of vulnerable plaque. Expert Rev Mol Med 2016; 18:e6. [PMID: 27056676 DOI: 10.1017/erm.2016.5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Cardiovascular diseases are the leading cause of death in developed countries. The aetiology is currently multifactorial, thus making them very difficult to prevent. Preclinical models of atherothrombotic diseases, including vulnerable plaque-associated complications, are now providing significant insights into pathologies like atherosclerosis, and in combination with the most recent advances in new non-invasive imaging technologies, they have become essential tools to evaluate new therapeutic strategies, with which can forecast and prevent plaque rupture. Positron emission tomography (PET)/computed tomography imaging is currently used for plaque visualisation in clinical and pre-clinical cardiovascular research, albeit with significant limitations. However, the combination of PET and magnetic resonance imaging (MRI) technologies is still the best option available today, as combined PET/MRI scans provide simultaneous data acquisition together with high quality anatomical information, sensitivity and lower radiation exposure for the patient. The coming years may represent a new era for the implementation of PET/MRI in clinical practice, but first, clinically efficient attenuation correction algorithms and research towards multimodal reagents and safety issues should be validated at the preclinical level.
Collapse
|
20
|
Winklhofer S, Peter S, Tischler V, Morsbach F, von Werdt M, Berens S, Modregger P, Buser L, Moch H, Stampanoni M, Thali M, Alkadhi H, Stolzmann P. Diagnostic Accuracy of Quantitative and Qualitative Phase-Contrast Imaging for the ex Vivo Characterization of Human Coronary Atherosclerotic Plaques. Radiology 2015; 277:64-72. [DOI: 10.1148/radiol.2015141614] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
21
|
Bakermans AJ, Abdurrachim D, Moonen RPM, Motaal AG, Prompers JJ, Strijkers GJ, Vandoorne K, Nicolay K. Small animal cardiovascular MR imaging and spectroscopy. PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 2015; 88-89:1-47. [PMID: 26282195 DOI: 10.1016/j.pnmrs.2015.03.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Revised: 03/09/2015] [Accepted: 03/09/2015] [Indexed: 06/04/2023]
Abstract
The use of MR imaging and spectroscopy for studying cardiovascular disease processes in small animals has increased tremendously over the past decade. This is the result of the remarkable advances in MR technologies and the increased availability of genetically modified mice. MR techniques provide a window on the entire timeline of cardiovascular disease development, ranging from subtle early changes in myocardial metabolism that often mark disease onset to severe myocardial dysfunction associated with end-stage heart failure. MR imaging and spectroscopy techniques play an important role in basic cardiovascular research and in cardiovascular disease diagnosis and therapy follow-up. This is due to the broad range of functional, structural and metabolic parameters that can be quantified by MR under in vivo conditions non-invasively. This review describes the spectrum of MR techniques that are employed in small animal cardiovascular disease research and how the technological challenges resulting from the small dimensions of heart and blood vessels as well as high heart and respiratory rates, particularly in mice, are tackled.
Collapse
Affiliation(s)
- Adrianus J Bakermans
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Desiree Abdurrachim
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Rik P M Moonen
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Abdallah G Motaal
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Jeanine J Prompers
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Gustav J Strijkers
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Katrien Vandoorne
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Klaas Nicolay
- Biomedical NMR, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.
| |
Collapse
|
22
|
Lin JB, Phillips EH, Riggins TE, Sangha GS, Chakraborty S, Lee JY, Lycke RJ, Hernandez CL, Soepriatna AH, Thorne BRH, Yrineo AA, Goergen CJ. Imaging of small animal peripheral artery disease models: recent advancements and translational potential. Int J Mol Sci 2015; 16:11131-77. [PMID: 25993289 PMCID: PMC4463694 DOI: 10.3390/ijms160511131] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Accepted: 03/10/2015] [Indexed: 12/11/2022] Open
Abstract
Peripheral artery disease (PAD) is a broad disorder encompassing multiple forms of arterial disease outside of the heart. As such, PAD development is a multifactorial process with a variety of manifestations. For example, aneurysms are pathological expansions of an artery that can lead to rupture, while ischemic atherosclerosis reduces blood flow, increasing the risk of claudication, poor wound healing, limb amputation, and stroke. Current PAD treatment is often ineffective or associated with serious risks, largely because these disorders are commonly undiagnosed or misdiagnosed. Active areas of research are focused on detecting and characterizing deleterious arterial changes at early stages using non-invasive imaging strategies, such as ultrasound, as well as emerging technologies like photoacoustic imaging. Earlier disease detection and characterization could improve interventional strategies, leading to better prognosis in PAD patients. While rodents are being used to investigate PAD pathophysiology, imaging of these animal models has been underutilized. This review focuses on structural and molecular information and disease progression revealed by recent imaging efforts of aortic, cerebral, and peripheral vascular disease models in mice, rats, and rabbits. Effective translation to humans involves better understanding of underlying PAD pathophysiology to develop novel therapeutics and apply non-invasive imaging techniques in the clinic.
Collapse
Affiliation(s)
- Jenny B Lin
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Evan H Phillips
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Ti'Air E Riggins
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Gurneet S Sangha
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Sreyashi Chakraborty
- School of Mechanical Engineering, Purdue University, West Lafayette, IN 47907, USA.
| | - Janice Y Lee
- Psychological Sciences, Purdue University, West Lafayette, IN 47907, USA.
| | - Roy J Lycke
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Clarissa L Hernandez
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Arvin H Soepriatna
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Bradford R H Thorne
- School of Sciences, Neuroscience, Purdue University, West Lafayette, IN 47907, USA.
| | - Alexa A Yrineo
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| | - Craig J Goergen
- Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, Room 3025, West Lafayette, IN 47907, USA.
| |
Collapse
|
23
|
Lavin B, Phinikaridou A, Henningsson M, Botnar RM. Current Development of Molecular Coronary Plaque Imaging using Magnetic Resonance Imaging towards Clinical Application. CURRENT CARDIOVASCULAR IMAGING REPORTS 2014. [DOI: 10.1007/s12410-014-9309-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Bigalke B, Phinikaridou A, Andia ME, Cooper MS, Schuster A, Wurster T, Onthank D, Münch G, Blower P, Gawaz M, Nagel E, Botnar RM. PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). Int J Cardiol 2014; 177:287-91. [PMID: 25499394 DOI: 10.1016/j.ijcard.2014.09.017] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 08/25/2014] [Accepted: 09/15/2014] [Indexed: 02/06/2023]
Abstract
Continued uptake of modified low-density lipoproteins (LDL) by the scavenger receptor, CD68, of activated macrophages is a crucial process in the development of atherosclerotic plaques and leads to the formation of foam cells. Eight-weeks-old male Apolipoprotein E-deficient (ApoE(-/-)) mice (n = 6) were fed a high-fat diet for 12 weeks. C57BL/6J wildtype (WT) mice served as controls (n = 6). Positron emission tomography (PET) with an acquisition time of 1800 s (NanoPET/CT scanner; Mediso, Hungary & Bioscan, USA) was carried out 24h after intravenous tail vein administration of 50 µl (64)Cu-CD68-Fc (~20-30 µg labeled protein/mouse containing approximately 10-12 MBq (64)Cu-CD68-Fc per mouse). Three days after PET/CT, all mice received an intravenous administration of 0.2 mmol/kg body weight of a gadolinium-based elastin-binding contrast agent to assess plaque burden and vessel wall remodeling. Two hours after injection, mice were imaged in a 3T clinical MR scanner (Philips Healthcare, Best, NL) using a dedicated single loop surface coil (23 mm). Enhanced (64)Cu-CD68-Fc uptake was found in the aortic arches of ApoE(-/-) compared to WT mice (ApoE(-/-) mice:10.5 ± 1.5 Bq/cm(3) vs. WT mice: 2.1 ± 0.3 Bq/cm(3); P = 0.002). Higher gadolinium-based elastin-binding contrast agent uptake was also detected in the aortic arch of ApoE(-/-) compared to WT mice using R(1) maps (R(1) = 1.47 ± 0.06 s(-1) vs. 0.92 ± 0.05 s(-1); P <0.001). Radiolabeled scavenger receptor ((64)Cu-CD68-Fc) may help to target foam cell rich plaques with high content of oxidized LDL. This novel imaging biomarker tool may have potential to identify unstable plaques and for risk stratification.
Collapse
MESH Headings
- Animals
- Antigens, CD/metabolism
- Antigens, Differentiation, Myelomonocytic/metabolism
- Carotid Artery, Common/diagnostic imaging
- Carotid Artery, Common/pathology
- Copper Radioisotopes
- Disease Models, Animal
- Magnetic Resonance Imaging/methods
- Male
- Mice
- Mice, Inbred C57BL
- Plaque, Atherosclerotic/diagnosis
- Plaque, Atherosclerotic/metabolism
- Positron-Emission Tomography/methods
- Receptors, Scavenger/metabolism
- Reproducibility of Results
- Tomography, X-Ray Computed/methods
Collapse
Affiliation(s)
- Boris Bigalke
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom; Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Medizinische Klinik für Kardiologie und Pulmologie, Berlin, Germany
| | - Alkystis Phinikaridou
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom
| | - Marcelo E Andia
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom; Radiology Department, School of Medicine, Pontificia Universidad Catolica de Chile, Chile
| | - Margaret S Cooper
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom
| | - Andreas Schuster
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom; Department of Cardiology and Pulmonology, Georg-August-University, Göttingen, Germany; Department of Cardiology and Pulmonology, German Centre for Cardiovascular Research (DZHK Partner Site), Göttingen, Germany
| | - Thomas Wurster
- Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Germany
| | | | | | - Philip Blower
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom
| | - Meinrad Gawaz
- Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Germany
| | - Eike Nagel
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom; BHF Centre of Excellence, King's College London, United Kingdom; Wellcome Trust and EPSRC Medical Engineering Center, King's College London, United Kingdom; NIHR Biomedical Research Centre, King's College London, London, United Kingdom
| | - Rene M Botnar
- King's College London, Division of Imaging Sciences and Biomedical Engineering, London, United Kingdom; AdvanceCor GmbH, Martinsried, Germany; Wellcome Trust and EPSRC Medical Engineering Center, King's College London, United Kingdom; NIHR Biomedical Research Centre, King's College London, London, United Kingdom.
| |
Collapse
|